vs

Side-by-side financial comparison of Equifax (EFX) and Steris (STE). Click either name above to swap in a different company.

Equifax is the larger business by last-quarter revenue ($1.6B vs $1.5B, roughly 1.0× Steris). Steris runs the higher net margin — 12.9% vs 11.3%, a 1.6% gap on every dollar of revenue. On growth, Equifax posted the faster year-over-year revenue change (9.2% vs 9.2%). Equifax produced more free cash flow last quarter ($340.8M vs $199.5M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 5.6%).

Equifax Inc. is an American multinational consumer credit reporting agency headquartered in Atlanta, Georgia and is one of the three largest consumer credit reporting agencies, along with Experian and TransUnion. Equifax collects and aggregates information on more than 800 million individual consumers and more than 88 million businesses worldwide.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

EFX vs STE — Head-to-Head

Bigger by revenue
EFX
EFX
1.0× larger
EFX
$1.6B
$1.5B
STE
Growing faster (revenue YoY)
EFX
EFX
+0.1% gap
EFX
9.2%
9.2%
STE
Higher net margin
STE
STE
1.6% more per $
STE
12.9%
11.3%
EFX
More free cash flow
EFX
EFX
$141.3M more FCF
EFX
$340.8M
$199.5M
STE
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
5.6%
EFX

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
EFX
EFX
STE
STE
Revenue
$1.6B
$1.5B
Net Profit
$175.7M
$192.9M
Gross Margin
43.8%
Operating Margin
18.3%
18.3%
Net Margin
11.3%
12.9%
Revenue YoY
9.2%
9.2%
Net Profit YoY
1.0%
11.2%
EPS (diluted)
$1.44
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EFX
EFX
STE
STE
Q4 25
$1.6B
$1.5B
Q3 25
$1.5B
$1.5B
Q2 25
$1.5B
$1.4B
Q1 25
$1.4B
$1.5B
Q4 24
$1.4B
$1.4B
Q3 24
$1.4B
$1.3B
Q2 24
$1.4B
$1.3B
Q1 24
$1.4B
$1.1B
Net Profit
EFX
EFX
STE
STE
Q4 25
$175.7M
$192.9M
Q3 25
$160.2M
$191.9M
Q2 25
$191.3M
$177.4M
Q1 25
$133.1M
$145.7M
Q4 24
$174.0M
$173.5M
Q3 24
$141.3M
$150.0M
Q2 24
$163.9M
$145.4M
Q1 24
$124.9M
$-1.4M
Gross Margin
EFX
EFX
STE
STE
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
43.6%
Q2 24
44.7%
Q1 24
40.2%
Operating Margin
EFX
EFX
STE
STE
Q4 25
18.3%
18.3%
Q3 25
17.1%
18.2%
Q2 25
20.2%
17.7%
Q1 25
16.4%
14.6%
Q4 24
20.3%
17.9%
Q3 24
17.1%
16.5%
Q2 24
19.7%
14.5%
Q1 24
16.2%
22.0%
Net Margin
EFX
EFX
STE
STE
Q4 25
11.3%
12.9%
Q3 25
10.4%
13.1%
Q2 25
12.4%
12.8%
Q1 25
9.2%
9.8%
Q4 24
12.3%
12.7%
Q3 24
9.8%
11.3%
Q2 24
11.5%
11.4%
Q1 24
9.0%
-0.1%
EPS (diluted)
EFX
EFX
STE
STE
Q4 25
$1.44
$1.96
Q3 25
$1.29
$1.94
Q2 25
$1.53
$1.79
Q1 25
$1.06
$1.48
Q4 24
$1.40
$1.75
Q3 24
$1.13
$1.51
Q2 24
$1.31
$1.46
Q1 24
$1.00
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EFX
EFX
STE
STE
Cash + ST InvestmentsLiquidity on hand
$180.8M
$423.7M
Total DebtLower is stronger
$5.1B
$1.9B
Stockholders' EquityBook value
$4.6B
$7.2B
Total Assets
$11.9B
$10.6B
Debt / EquityLower = less leverage
1.11×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EFX
EFX
STE
STE
Q4 25
$180.8M
$423.7M
Q3 25
$189.0M
$319.2M
Q2 25
$189.0M
$279.7M
Q1 25
$195.2M
$171.7M
Q4 24
$169.9M
$155.2M
Q3 24
$468.2M
$172.2M
Q2 24
$181.9M
$198.3M
Q1 24
$201.0M
$207.0M
Total Debt
EFX
EFX
STE
STE
Q4 25
$5.1B
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$5.0B
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
EFX
EFX
STE
STE
Q4 25
$4.6B
$7.2B
Q3 25
$4.9B
$7.0B
Q2 25
$5.1B
$7.0B
Q1 25
$5.0B
$6.6B
Q4 24
$4.8B
$6.4B
Q3 24
$4.9B
$6.6B
Q2 24
$4.7B
$6.4B
Q1 24
$4.6B
$6.3B
Total Assets
EFX
EFX
STE
STE
Q4 25
$11.9B
$10.6B
Q3 25
$11.8B
$10.4B
Q2 25
$11.9B
$10.4B
Q1 25
$11.9B
$10.1B
Q4 24
$11.8B
$10.0B
Q3 24
$12.3B
$10.2B
Q2 24
$12.2B
$10.1B
Q1 24
$12.3B
$11.1B
Debt / Equity
EFX
EFX
STE
STE
Q4 25
1.11×
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
1.05×
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EFX
EFX
STE
STE
Operating Cash FlowLast quarter
$470.8M
$298.2M
Free Cash FlowOCF − Capex
$340.8M
$199.5M
FCF MarginFCF / Revenue
22.0%
13.3%
Capex IntensityCapex / Revenue
8.4%
6.6%
Cash ConversionOCF / Net Profit
2.68×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$1.1B
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EFX
EFX
STE
STE
Q4 25
$470.8M
$298.2M
Q3 25
$559.9M
$287.8M
Q2 25
$361.1M
$420.0M
Q1 25
$223.9M
$260.8M
Q4 24
$324.8M
$332.8M
Q3 24
$479.5M
$250.7M
Q2 24
$267.5M
$303.7M
Q1 24
$252.7M
$254.8M
Free Cash Flow
EFX
EFX
STE
STE
Q4 25
$340.8M
$199.5M
Q3 25
$437.9M
$201.3M
Q2 25
$238.9M
$326.4M
Q1 25
$116.7M
$189.9M
Q4 24
$205.9M
$243.6M
Q3 24
$355.5M
$148.8M
Q2 24
$130.8M
$195.7M
Q1 24
$120.8M
$163.3M
FCF Margin
EFX
EFX
STE
STE
Q4 25
22.0%
13.3%
Q3 25
28.3%
13.8%
Q2 25
15.5%
23.5%
Q1 25
8.1%
12.8%
Q4 24
14.5%
17.8%
Q3 24
24.7%
11.2%
Q2 24
9.1%
15.3%
Q1 24
8.7%
14.6%
Capex Intensity
EFX
EFX
STE
STE
Q4 25
8.4%
6.6%
Q3 25
7.9%
5.9%
Q2 25
8.0%
6.7%
Q1 25
7.4%
4.8%
Q4 24
8.4%
6.5%
Q3 24
8.6%
7.7%
Q2 24
9.6%
8.4%
Q1 24
9.5%
8.2%
Cash Conversion
EFX
EFX
STE
STE
Q4 25
2.68×
1.55×
Q3 25
3.50×
1.50×
Q2 25
1.89×
2.37×
Q1 25
1.68×
1.79×
Q4 24
1.87×
1.92×
Q3 24
3.39×
1.67×
Q2 24
1.63×
2.09×
Q1 24
2.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EFX
EFX

United States Consumer Information Solutions$1.5B95%
Employer Services$95.3M6%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons